118 tracked 13F filers disclose a position in CCCC as of the latest SEC 13F filings, a combined $318.5M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | $23.9M | 9.1M | ▲+1.0% Added · +91K sh | Q1 2026 | |
| 2 | RA CAPITAL MANAGEMENT, L.P. | $21.0M | 8.0M | —Held | Q1 2026 | |
| 3 | Lynx1 Capital Management LP | $34.2M | 7.3M | ▲+4.7% Added · +328K sh | Q2 2026 | |
| 4 | Bain Capital Life Sciences Investors, LLC | $33.5M | 7.2M | —Held | Q2 2026 | |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $10.2M | 3.9M | →First observed position No prior filed position | Q1 2026 | |
| 6 | WASATCH ADVISORS LP | $16.5M | 3.5M | ▲+19% Added · +561K sh | Q2 2026 | |
| 7 | Soleus Capital Management, L.P. | $15.8M | 3.4M | ▼−11% Reduced · −426K sh | Q2 2026 | |
| 8 | JPMORGAN CHASE & CO | $7.6M | 3.2M | ▲542× Added · +3.2M sh | Q1 2026 | |
| 9 | TWO SIGMA INVESTMENTS, LP | $8.0M | 3.0M | ▲+101% Added · +1.5M sh | Q1 2026 | |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | $14.2M | 3.0M | ▲+59% Added · +1.1M sh | Q2 2026 | |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | $11.8M | 2.5M | ▲+165% Added · +1.6M sh | Q2 2026 | |
| 12 | CITADEL ADVISORS LLC | $6.6M | 2.5M | ▲+461% Added · +2.1M sh | Q1 2026 | |
| 13 | RENAISSANCE TECHNOLOGIES LLC | $6.5M | 2.5M | ▲+54% Added · +859K sh | Q1 2026 | |
| 14 | GOLDMAN SACHS GROUP INC | $6.3M | 2.4M | ▲+119% Added · +1.3M sh | Q1 2026 | |
| 15 | BANK OF AMERICA CORP /DE/ | $6.2M | 2.4M | ▼−1.2% Reduced · −28K sh | Q1 2026 | |
| 16 | Squadron Capital Management LLC | $5.9M | 2.3M | ▲New +2.3M sh | Q1 2026 | |
| 17 | STATE STREET CORP | $9.9M | 2.1M | ▲+452% Added · +1.7M sh | Q2 2026 | |
| 18 | BlackRock, Inc. | $5.4M | 2.0M | ▲+4.0% Added · +79K sh | Q1 2026 | |
| 19 | Candriam S.C.A. | $8.4M | 1.8M | ▲New +1.8M sh | Q2 2026 | |
| 20 | Patient Square Capital LP | $7.5M | 1.6M | ▲New +1.6M sh | Q2 2026 | |
| 21 | MILLENNIUM MANAGEMENT LLC | $3.7M | 1.4M | ▲+17% Added · +204K sh | Q1 2026 | |
| 22 | HighVista Strategies LLC | $6.3M | 1.3M | ▲New +1.3M sh | Q2 2026 | |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3.4M | 1.3M | ▼−28% Reduced · −489K sh | Q1 2026 | |
| 24 | JANE STREET GROUP, LLC | $3.3M | 1.2M | ▲+43% Added · +372K sh | Q1 2026 | |
| 25 | D. E. Shaw & Co., Inc. | $2.8M | 1.1M | ▲20× Added · +1.0M sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 18 funds opened a new position in CCCC and 23 added to an existing one, while 14 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| AMAZON.COM INCAMZN | 61 funds | $52.5B |
| NVIDIA CORPNVDA | 60 funds | $113.2B |
| MICROSOFT CORPMSFT | 60 funds | $71.5B |
| ALPHABET INC-CL CGOOG | 57 funds | $33.4B |
| META PLATFORMS INC-CLASS AMETA | 57 funds | $32.9B |
| ALPHABET INC-CL AGOOGL | 55 funds | $46.0B |
| BROADCOM INCAVGO | 55 funds | $45.1B |
| ELI LILLY & COLLY | 55 funds | $21.5B |
| VISA INC-CLASS A SHARESV | 55 funds | $18.2B |
| MICRON TECHNOLOGY INCMU | 55 funds | $14.2B |
| BERKSHIRE HATHAWAY INC-CL BBRK/B | 54 funds | $9.6B |
| APPLE INCAAPL | 53 funds | $87.1B |
Ranked by how many of CCCC's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jan 16, 2026 | REYNO LEONARD | Chief Medical Officer | Sell (S) | 10K | $22K |
| Feb 18, 2025 | Boyle Scott N | Chief Business Officer | Sell (S) | 669 | $2K |
| Feb 14, 2025 | Boyle Scott N | Chief Business Officer | Sell (S) | 490 | $2K |
| Feb 8, 2023 | Koppikar Utpal | Director | Buy (P) | 6K | $32K |
| Apr 12, 2022 | Hirsch Andrew | President & CEO, Director | Buy (P) | 10K | $84K |
| Jan 4, 2022 | Crystal Adam | Chief Medical Officer | Sell (S) | 1K | $34K |
| Jan 4, 2022 | Crystal Adam | Chief Medical Officer | Sell (S) | 14K | $441K |
| Dec 17, 2021 | Salter Malcolm | Director | Sell (S) | 755 | $23K |
| Nov 19, 2021 | Salter Malcolm | Director | Sell (S) | 755 | $30K |
| Oct 15, 2021 | Salter Malcolm | Director | Sell (S) | 755 | $34K |
| Oct 1, 2021 | Crystal Adam | Chief Medical Officer | Sell (S) | 8K | $371K |
| Oct 1, 2021 | Crystal Adam | Chief Medical Officer | Sell (S) | 2K | $76K |
Connected entities for CCCC
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/CCCC/capital-change-brief"
Use Arkolith's capital_change_brief for CCCC. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for CCCC. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.